What difference can a few drops of blood make? Part 1 - Meet Emily Goff
When you take part in TrialNet type 1 diabetes (T1D) risk screening, a few drops of blood can make a big difference. In addition to learning your risk for developing T1D—often years before symptoms appear—you’re joining the TrialNet #T1Dfamily, the world’s largest clinical trial network ever assembled to change the course of T1D.
Meet new TrialNet Chair, Dr. Kevan Herold
Kevan C. Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology) at Yale School of Medicine, was recently appointed TrialNet Chair, succeeding Carla J. Greenbaum, MD, who served six years in the position.
Research interest leads first participant to join groundbreaking TOPPLE T1D study
|
TrialNet Research Continues to Close in on Type 1 Diabetes Prevention
New TrialNet research findings published today in Science Translational Medicine show that a 14-day course of the immunotherapy drug teplizumab provided an additional year of delay in onset of type 1 diabetes and improved insulin production, increasing the overall benefit to high-risk individuals reported in the original study fin
TrialNet Launches New Study Exploring Plasmid Therapy
Now enrolling adults diagnosed with T1D in the past 4 years
TrialNet is excited to announce the launch of our first Phase 1 clinical study to test a new plasmid therapy. The study will enroll 48 adults (age 18-45) diagnosed with type 1 diabetes (T1D) in the past 4 years.
TrialNet highlights research advances during Diabetes Awareness Month and World Diabetes Day
Each November, we join the diabetes community to recognize Diabetes Awareness Month and World Diabetes Day on November 14th. This year, as TrialNet begins to celebrate 20 years, we share major research advances made possible by our incredible study participants and research teams around the world.
Identifying early stages of T1D
You can still make a difference from home with a TrialNet in-home risk screening kit
During this difficult time for families around the world, staying at home is vitally important to controlling the spread of COVID-19. And, we’re continually amazed and thankful to see all the ways families are finding ways to make a difference.
TrialNet remains committed to T1D research during the COVID-19 pandemic
A message from TrialNet Chair Carla Greenbaum, M.D.
At TrialNet, the health and safety of our participants and research teams is always our top priority.
Tracy Olsten shares why her daughter Mikayla participated in the landmark Teplizumab prevention trial
With landmark results recently announced, the Teplizumab Prevention Study is making headlines across the country. Here, Tracy Olsten shares why her daughter Mikayla decided to join the study.